AI skin cancer detection: which startup is ahead?
In our digital health market deck, you will find everything you need to understand the market
SUMMARY
Skin Analytics is currently ahead in AI skin cancer detection, with DermaSensor as the strongest clinical challenger and SkinVision leading the consumer side of the market.
The category looks less unified than the headline suggests. These startups compete at different points in care, from home spot checks to primary-care referral decisions and autonomous assessment inside hospital pathways.
Skin Analytics’ advantage comes from convergence rather than one spectacular metric. It combines Class III authorization, six years inside NHS pathways, more than 230,000 assessed patients, over 20,000 identified cancers, and publicly visible contracts.
DermaSensor owns the clearest U.S. opening. Its FDA De Novo clearance, distinctive spectroscopy hardware, and rapid early scan growth give it a credible route into primary care, although its current clinical footprint remains much smaller.
SkinVision has achieved something the clinical-device companies have not: mass consumer distribution. More than six million checks prove reach and repeat use, but not yet the same level of verified clinical impact.
The accuracy comparison is easy to misuse. DermaSensor’s pivotal study produced strong sensitivity but low specificity, while DERM’s specificity varied materially across NHS pathways; Dermalyser’s attractive result came from a much smaller melanoma sample.
Commercial evidence also separates the leaders. Skin Analytics has disclosed multi-year public procurement awards worth about £3.5 million before VAT, while rivals generally report users, physicians, partnerships, or customers without comparable contract detail.
On growth, DermaSensor is moving fastest in percentage terms, but Skin Analytics is adding far more consequential clinical volume. SkinVision is widening the distribution gap through software rather than hospital deployment.
The hardest moat is not the image classifier itself. Skin Analytics has accumulated pathology-linked outcomes and workflow experience, DermaSensor has protected hardware and calibration know-how, and SkinVision has a large direct relationship with consumers.
The ranking could still change. Skin Analytics must prove it can expand beyond the NHS, DermaSensor must turn early physician adoption into large deployments and resolve its recall, and SkinVision needs U.S. authorization plus evidence that app alerts lead to better outcomes and lower costs.
This market map, featured in our digital health market deck, highlights top companies and startups in the digital health market
Which AI skin cancer detection startups are actually comparable?
The core AI skin cancer detection race currently includes Skin Analytics, DermaSensor, SkinVision, and AI Medical Technology, with MetaOptima and SkinIO competing more indirectly through imaging and long-term monitoring.
The products solve different parts of the same problem. Skin Analytics helps healthcare systems assess and triage suspected cancers. DermaSensor gives primary-care physicians an immediate referral recommendation. SkinVision lets consumers check individual spots with a smartphone. AI Medical Technology’s Dermalyser supports clinicians assessing possible melanoma.
MetaOptima and SkinIO belong at the edge of the comparison. Both help clinicians capture, organize, and compare skin images, but neither has shown the same level of autonomous diagnostic responsibility as Skin Analytics or the same U.S. regulatory position as DermaSensor.
We excluded academic algorithms without a commercial product, broad symptom-checking apps, and preventive health companies that inspect the skin as one small part of a full-body assessment. We also excluded FotoFinder from the startup ranking. Its Moleanalyzer product is relevant, but FotoFinder was founded in 1991 and now competes as an established medical-imaging company.
Funding figures remain approximate. Private databases count grants, convertible notes, and older rounds differently, so ranges are more honest than false precision.
| Startup | Main AI skin cancer product | Approximate funding raised | Why it belongs |
|---|---|---|---|
| Skin Analytics | DERM and DERM Zero for autonomous lesion assessment and triage | $25 million to $33 million | Leading health-system platform |
| DermaSensor | Handheld spectroscopy device for primary-care referral decisions | $43 million | Leading U.S. clinical device |
| SkinVision | Consumer smartphone app for skin-spot risk assessment | About $11 million | Leading consumer platform |
| AI Medical Technology | Dermalyser for clinician-supported melanoma assessment | At least $2 million disclosed | Emerging European clinical competitor |
| MetaOptima | DermEngine and OptimaScan imaging and monitoring tools | About $9 million | Adjacent clinical workflow platform |
| SkinIO | Smartphone total-body photography and change monitoring | About $5 million | Adjacent monitoring platform |
Is Skin Analytics already the clear AI skin cancer detection leader?
Skin Analytics is currently ahead overall in AI skin cancer detection, while DermaSensor and SkinVision lead narrower parts of the market.
Skin Analytics has the strongest combination of regulatory authority, routine clinical use, public contracts, and verified cancer outcomes. DERM has operated inside NHS pathways for six years, and the company has now extended the technology to autonomous assessments captured with a standard smartphone through DERM Zero.
DermaSensor has built the strongest position in American primary care. The FDA granted the device De Novo clearance, hundreds of physicians have reportedly adopted it, and the company has since obtained a European Class IIb CE mark. Its clinical scale, however, remains far below Skin Analytics.
SkinVision leads consumer distribution. Its smartphone app has completed millions of checks, which no hospital-based competitor can match. Yet a consumer risk indication carries less clinical weight than an assessment embedded in an urgent cancer pathway and followed through to biopsy or discharge.
The market therefore has one overall leader and two serious specialists. Skin Analytics leads health-system deployment. DermaSensor leads U.S. physician access. SkinVision leads direct-to-consumer reach. AI Medical Technology remains a credible but much earlier fourth competitor.
If you want more recent data on this point, please see our latest digital health market report.
As this chart shows, and as featured in our digital health market deck, search interest in longevity apps and related topics has been increasing
Which AI skin cancer startup is assessing the most real patients?
Skin Analytics leads real-world AI skin cancer assessment by more than an order of magnitude over its closest clinical startup competitor.
According to Skin Analytics’ latest operating disclosure, DERM has assessed more than 230,000 NHS patients and identified over 20,000 cancers. Those cancers are checked against histopathology, giving the company an unusually valuable connection between the AI result and the final medical outcome.
DermaSensor had passed 20,000 lesion scans by October 2025. The company said roughly 2,000 scans led to referrals for suspicious cancers. Those referrals still required specialist assessment, so they cannot be counted as confirmed cancers.
The rough scale gap is striking. Skin Analytics has assessed more than eleven times as many patients as DermaSensor has disclosed scans. Patients and lesions are different units, and the two products operate at different points in care, but the comparison still shows how far apart their current clinical footprints are.
SkinVision operates on a much larger consumer scale, with more than six million checks. An app check may involve a user photographing one spot at home, while a clinical assessment can lead directly to discharge, referral, or biopsy. We therefore treat SkinVision’s volume as evidence of reach rather than equivalent medical throughput.
AI Medical Technology has published prospective results for Dermalyser, but it has not released enough commercial-use data to join the scale comparison. MetaOptima reports millions of stored images, although image storage and lesion monitoring reveal little about how often its AI changed a clinical decision.
Which AI skin cancer startup has the strongest regulatory and clinical proof?
Skin Analytics has the strongest overall package of regulation and real-world evidence, while DermaSensor has produced the strongest U.S. pivotal trial.
DERM holds a European Class III CE mark that allows it to make autonomous skin cancer decisions without routine clinician approval. NICE currently permits the technology inside NHS teledermatology services during a three-year evidence-generation period, with the service paid through core NHS funding.
That NICE position remains conditional. The agency requires continued performance monitoring and professional review for people with black or brown skin while further evidence is gathered. Skin Analytics has reached routine use, but it still has important work to do before NICE considers permanent nationwide adoption.
The scale of the existing evidence gives Skin Analytics the edge. NICE reviewed company data covering 85,955 lesions from 72,390 people. DERM reached 97% sensitivity across cancers and 95% for melanoma in that dataset, although NICE found that the most comparable recent-version outcome data covered a smaller group.
DermaSensor’s FDA study was more controlled. It enrolled 1,005 people with 1,579 suspicious lesions across 22 sites in the United States and Australia. Every lesion was biopsied and compared with central dermatopathology. The device reached 95.5% sensitivity across melanoma, basal cell carcinoma, and squamous cell carcinoma.
The FDA clearance has narrower boundaries than Skin Analytics’ European authorization. DermaSensor is intended for patients aged 40 and older, after a non-dermatologist physician has already decided that a lesion looks suspicious. It helps with referral decisions and does not screen the general population, confirm a diagnosis, or replace a biopsy.
SkinVision holds an EU MDR Class IIa certification. Its current collaboration with Mayo Clinic is supporting a pivotal study required for its planned U.S. regulatory pathway. Dermalyser is CE marked for professional melanoma decision support and has entered European commercialization.
Today, Skin Analytics has the deepest clinical history. DermaSensor has the cleanest regulatory trial. SkinVision has achieved wide access before U.S. authorization, while Dermalyser still needs a much larger body of use outside its initial study.
This chart, featured in our digital health market deck, shows annual VC investment in digital health startups
Which AI skin cancer product catches cancer without flooding specialists with referrals?
Skin Analytics currently offers the strongest practical balance between catching cancers and reducing unnecessary specialist work, although its specificity has varied across NHS settings.
Sensitivity measures how many cancers a system catches. Specificity measures how often it correctly leaves benign lesions alone. High sensitivity with weak specificity may protect against missed cancers, but it can also send large numbers of people for avoidable appointments and biopsies.
DermaSensor shows the trade-off clearly. Its FDA pivotal study reported 95.5% overall sensitivity and 20.7% specificity. About four out of five benign lesions therefore produced a positive result when the device was used alone. The FDA accepted that performance for an adjunctive tool applied only after a physician had identified a suspicious lesion.
DERM’s reviewed specificity ranged from roughly 45% to more than 70%, depending on the study and pathway. That variation prevents us from presenting one universal performance number. Even so, NICE’s economic assessment found that autonomous use could remove around half of eligible cases from dermatologist review.
Dermalyser reported a stronger-looking combination, with approximately 95% sensitivity and 85% specificity. Its prospective study included only 21 melanomas, however, so a single additional missed cancer would have moved the sensitivity result by almost five percentage points.
A recent meta-analysis of prospective melanoma studies adds useful context. Across 11 studies involving more than 2,500 patients, AI used alone achieved roughly 81% sensitivity and 76% specificity. The only study examining clinicians assisted by AI produced higher performance on both measures, supporting the idea that decision support may remain safer than full automation in many settings.
| Product | Main evidence base | Sensitivity | Specificity | Our reading |
|---|---|---|---|---|
| Skin Analytics DERM | Large NHS real-world datasets | About 95% to 97% | Roughly 45% to 73% | Best evidence of useful triage at scale, with meaningful variation between pathways |
| DermaSensor | 1,579 biopsied suspicious lesions | 95.5% overall | 20.7% | Strong rule-out sensitivity, but many benign lesions still trigger referrals |
| Dermalyser | 253 lesions, including 21 melanomas | About 95% | About 85% | Promising result from a small melanoma sample |
| SkinVision | Earlier independent app studies | Around 80% | Around 78% | Useful consumer guidance, but weaker evidence for standalone clinical reliance |
If you want more recent data on this point, please see our latest digital health market report.
Does SkinVision’s consumer reach make it the AI skin cancer leader?
SkinVision is the clear consumer leader in AI skin cancer detection, but its millions of checks do not yet outweigh Skin Analytics’ clinical deployment.
SkinVision has supported more than six million checks for over three million users, equivalent to roughly two checks per user. That is far greater public reach than any other startup in the field.
The recent trajectory is also strong. SkinVision moved from more than five million checks in August 2025 to more than six million by March 2026. The app added at least one million checks in around seven months, increasing its lifetime volume by roughly 20%.
Smartphone distribution explains part of that speed. SkinVision can expand through app stores, insurers, employers, and healthcare partners without shipping physical devices or rebuilding hospital workflows. Each new user brings limited marginal cost.
The clinical value remains harder to measure. Users decide which spots to photograph, image quality varies, and the app provides an indication that a lesion may deserve professional attention. SkinVision does not diagnose cancer or control what happens after a high-risk result.
The Mayo Clinic pivotal trial could narrow that gap. FDA authorization, followed by insurer-funded access and reliable connections to dermatology care, would turn SkinVision’s reach into a much stronger competitive advantage. For now, the company leads discovery and accessibility rather than confirmed clinical impact.
This chart, featured in our digital health market deck, shows how Hinge Health captured share in digital health
Which AI skin cancer startup has won the strongest customers and contracts?
Skin Analytics has the strongest commercial traction because healthcare systems are buying DERM for routine cancer pathways through large, multi-year contracts.
Two British public procurement awards announced in 2026 make that traction unusually visible for a private medical AI company. Northern Ireland’s health authorities awarded Skin Analytics a contract worth £2.74 million before VAT for the DERM application and platform. The initial period runs through March 2027, with extensions available through March 2029.
Bradford Teaching Hospitals awarded a separate contract worth £764,304 before VAT, initially covering three years with possible extensions to five. The procurement notice cited Skin Analytics’ autonomous capability as the technical reason for a direct award.
Together, those two disclosed awards represent about £3.5 million of contracted value before VAT. They also show two different forms of adoption: one regional platform purchase and one hospital deployment with a potential five-year lifespan.
DermaSensor has reported hundreds of physicians using its device across health systems and private practices. That is genuine commercial activity, although the company has not disclosed contract values, revenue, renewal rates, devices per customer, or average scans per physician.
SkinVision has distribution relationships with insurers and a major clinical research collaboration with Mayo Clinic. We still lack the figures needed to separate free access, employer-sponsored checks, insured usage, and individually paying subscribers.
AI Medical Technology says Dermalyser already has customers in Europe, but it has released little information about deployment counts or repeat orders. MetaOptima appears well established inside dermatology imaging workflows, although its commercial disclosures are similarly limited.
Skin Analytics wins this comparison because public procurement records confirm that buyers are committing material budgets and several years of operations to the product.
Which AI skin cancer startup is growing fastest now?
DermaSensor is growing fastest in percentage terms, while Skin Analytics is adding the most consequential clinical volume.
DermaSensor reported average quarterly scan growth of 117% between its mid-2024 U.S. launch and October 2025. Such growth is possible partly because the company started from a very small commercial base, but passing 20,000 scans still shows that physicians are using the device beyond a handful of trials.
Skin Analytics grew from more than 150,000 assessed patients and 14,000 detected cancers in April 2025 to over 230,000 patients and 20,000 cancers by June 2026. That means patient volume rose by at least 53%, while identified cancers increased by about 43% over roughly 14 months.
The absolute additions are substantial: at least 80,000 more patients and 6,000 more cancers. Skin Analytics processed around four times DermaSensor’s entire disclosed scan base during that period alone.
SkinVision added at least one million consumer checks in approximately seven months. That is an impressive distribution achievement, although it reflects a different and lighter form of interaction than a physician-led assessment.
AI Medical Technology made a different kind of leap by moving Dermalyser from clinical validation into CE-marked commercialization. That milestone changes the company’s prospects, but we have not yet seen the customer growth needed to compare it with the top three.
DermaSensor is currently the fastest challenger. Skin Analytics is extending its lead through larger absolute gains, and SkinVision continues to widen the consumer-reach gap.
If you want more recent data on this point, please see our latest digital health market report.
This chart, featured in our digital health market deck, shows annual funding in digital health startups
Which AI skin cancer product is mature enough to scale?
Skin Analytics has the most mature and scalable clinical product today because DERM has operated inside live NHS cancer pathways since 2020.
Six years of use brings exposure to cases that a controlled trial cannot reproduce fully: poor images, unusual lesions, changing hospital capacity, staff turnover, safety incidents, pathway redesigns, and patients who require alternative assessment.
Skin Analytics has also built the operational layer around the algorithm. DERM connects image capture, automated assessment, virtual review, patient communication, referral routing, biopsy outcomes, and continuing performance monitoring. Those processes explain why NHS partners have moved from pilots into autonomous deployment.
DERM Zero could simplify that model further. The new Class III product captures images through a standard smartphone, removing the dermoscopic attachment used in earlier DERM pathways. Skin Analytics is now working with European partners to bring the product into primary care, pharmacies, and community settings.
DermaSensor offers a simpler installation for individual practices. A physician can use the handheld device at the point of care without rebuilding an entire regional pathway. Scaling still requires manufacturing, calibration, maintenance, training, and reliable components across every deployed unit.
The FDA recall database currently lists a Class II DermaSensor recall as open. The issue concerns specified devices that might fail to meet technical requirements, potentially producing incorrect results or delaying referral. DermaSensor contacted affected customers and arranged device checks and corrections. The recall does not cover every unit, but it shows that hardware reliability has become part of the company’s scaling challenge.
SkinVision has already scaled as a consumer application. Its remaining challenge lies downstream, where users need access to professional assessment after a concerning result. Dermalyser has reached the European market but remains early in commercial deployment.
Which AI skin cancer startup offers healthcare systems the best economics?
Skin Analytics currently has the strongest evidence that its AI can save specialist time across an entire skin cancer pathway.
NICE lists DERM at £30 per referral, with an additional £8.20 when NHS teledermatology staff review the case. A combined discounted price of £35.90 is available when subsequent biopsy outcomes are shared with Skin Analytics.
The opportunity is large because only a small share of urgent referrals produce a cancer diagnosis. UK dermatology services receive around 1.2 million primary-care referrals each year, approximately 60% enter urgent suspected-cancer pathways, and only about 6% of urgent referrals are ultimately confirmed as cancer.
Put simply, around 94 of every 100 urgent referrals do not finish with a cancer diagnosis. Safely removing even a portion of those cases before a face-to-face appointment could release thousands of specialist hours.
NICE’s external assessment estimated that autonomous DERM could approximately halve referrals to dermatologists among eligible cases. The economics looked stronger against face-to-face assessment than against an efficient teledermatology service.
Eligibility limits reduce the addressable volume. NICE found that roughly one quarter of lesions in company data could not be assessed by DERM because of hair, nails, mucosal locations, image quality, or other restrictions. Healthcare providers still need a parallel route for those patients.
DermaSensor’s regular advertised price is $399 per month for unlimited users and scans. A practice performing 20 scans monthly would pay about $20 per scan. At 50 scans, the cost falls below $8. That pricing is accessible for an active U.S. primary-care clinic, although we lack independent evidence on referral savings, reimbursement, and avoided biopsies.
Skin Analytics leads at the health-system level. DermaSensor may offer the easiest financial entry for an individual clinic, while SkinVision can distribute basic risk guidance to very large populations at a low marginal cost.
This chart, featured in our digital health market deck, compares the main business model options for digital health SaaS platforms
What can the leading AI skin cancer startups do that rivals cannot easily copy?
Skin Analytics has built the hardest overall advantage to copy because its moat combines regulation, outcome data, NHS experience, and clinical workflow integration.
A competitor can train another lesion classifier. Recreating years of pathology-linked outcomes, hospital procurement experience, safety monitoring, patient communications, and autonomous pathway use requires far more time.
Skin Analytics says every cancer detected through DERM is checked against histopathology. That feedback gives the company data on final medical outcomes rather than images with uncertain labels. It can use those results to monitor performance across hospitals and patient groups.
DermaSensor’s strongest protection comes from its hardware. The device uses elastic scattering spectroscopy to measure how light interacts with tissue below the visible surface. A competitor would need to reproduce the optical system, manufacturing process, clinical dataset, calibration methods, and FDA-cleared algorithm.
SkinVision’s advantage comes from distribution. More than three million users, insurer relationships, consumer recognition, and years of smartphone interactions give the company a head start that a newly launched app would struggle to match.
MetaOptima has assembled a large dermatology image and workflow database. Its DermEngine platform may create switching costs for clinics that store years of patient images and comparisons inside the system.
AI Medical Technology is pursuing an embedding strategy through DermAIM, an API that can place its melanoma engine inside other healthcare platforms. That approach could let the company gain reach without building every workflow itself.
Skin Analytics currently owns the strongest full-stack position. DermaSensor has the most distinctive underlying technology, and SkinVision has the broadest direct relationship with consumers.
If you want more recent data on this point, please see our latest digital health market report.
Who leads each part of the AI skin cancer detection market today?
The AI skin cancer detection market has one overall leader but several specialized winners across clinical triage, primary care, consumer checks, and monitoring.
Skin Analytics leads the segment with the greatest immediate clinical responsibility: autonomous assessment inside healthcare systems. DermaSensor has the best entry into U.S. primary care, where physicians need fast help deciding whether to refer a suspicious lesion.
SkinVision dominates consumer spot checking. AI Medical Technology has built a credible melanoma-specific clinician tool, while MetaOptima and SkinIO focus more heavily on documenting change over time.
| AI skin cancer segment | Current leader | Why it leads now |
|---|---|---|
| Autonomous health-system triage | Skin Analytics | Class III authorization, routine NHS deployment, pathology-linked outcomes, and public contracts |
| U.S. primary-care decision support | DermaSensor | FDA De Novo clearance, point-of-care hardware, and rapid early adoption |
| Direct-to-consumer spot checking | SkinVision | Largest user base and the simplest route to broad consumer distribution |
| Melanoma-specific clinician support | AI Medical Technology | Strong prospective results and a CE-marked professional product |
| Clinical imaging and lesion workflow | MetaOptima | Established imaging infrastructure and a large longitudinal database |
| Smartphone total-body monitoring | SkinIO | Accessible photography designed to identify new or changing lesions |
This chart, featured in our digital health market deck, shows how revenue is split across customer segments in the digital health market
Which AI skin cancer startup uses its funding most effectively?
Skin Analytics currently appears more capital-efficient than DermaSensor, although private revenue and spending data remain too limited for a complete financial comparison.
DermaSensor has raised $43 million, compared with an estimated $25 million to $33 million for Skin Analytics. It therefore appears to have raised roughly 30% to 70% more capital.
Yet Skin Analytics’ disclosed clinical activity is around eleven times larger when we compare assessed patients with DermaSensor’s reported scans. The units and business models differ, so this should not be read as a precise productivity ratio. It still shows that having the largest funding total has not translated into the largest deployment.
SkinVision presents another form of efficiency. It has reportedly raised about $11 million and has reached millions of users through software distribution. We cannot judge the quality of that growth without revenue, retention, and follow-through data, but the company has achieved exceptional reach with much less capital than the two clinical leaders.
AI Medical Technology has reached prospective clinical validation and a European CE mark with only a few million dollars of publicly disclosed funding. That is a strong technical achievement. Commercialization will require more capital if the company needs sales teams, international studies, regulatory work, and integrations across several countries.
Funding strength still gives DermaSensor room to accelerate. Its latest $16 million round can support European expansion, additional evidence, product development, and U.S. sales. Skin Analytics’ £15 million Series B is similarly aimed at international growth and new dermatology products.
The current funding-efficiency leader is Skin Analytics because it has converted a smaller reported capital base into deeper clinical deployment and visible contract value.
How much can we trust the AI skin cancer startup numbers?
We can trust the broad competitive ranking, but several headline numbers remain company-reported and cannot be compared without adjusting for what they measure.
The strongest evidence comes from regulators, public health agencies, peer-reviewed prospective studies, histopathology results, and procurement databases. These sources establish what a product is legally allowed to do, how a study was designed, and whether a buyer has committed real money.
Operational volumes sit one level lower. Patient assessments, lesion scans, app checks, suspicious referrals, and stored images all measure different activities. Each figure is useful within its proper context, but combining them into one volume ranking would produce a false result.
Clinical accuracy also changes with the study population. Performance may shift according to cancer type, lesion selection, skin tone, age, image quality, device version, and whether the AI works alone or assists a clinician.
DermaSensor’s 95.5% headline sensitivity covers three common skin cancers. Its melanoma-only sensitivity was lower. Dermalyser’s excellent result came from 21 melanomas. DERM’s specificity has changed across NHS deployments. SkinVision’s latest certified version cannot be judged solely through studies of older app versions.
Representation remains a serious weakness. NICE requires professional review for DERM assessments involving black or brown skin while additional evidence is collected. The FDA also noted that DermaSensor had less evidence for darker Fitzpatrick skin types.
A recent prospective-study meta-analysis found that many AI melanoma studies still carry a high risk of patient-selection bias. Researchers often test systems on lesions already suspected of being melanoma, which produces a cleaner problem than screening a broad population in ordinary care.
We therefore have high confidence that Skin Analytics leads institutional deployment, DermaSensor leads U.S. regulatory access, and SkinVision leads consumer reach. We have less confidence when comparing revenue, retention, unit economics, and performance across skin tones because the public data remains incomplete.
This chart, featured in our digital health market deck, shows how remote patient monitoring platform technology has evolved over time
Which AI skin cancer startups are actually ahead?
Skin Analytics is the clear overall AI skin cancer detection leader today, with DermaSensor as the strongest clinical challenger and SkinVision as the leading consumer platform.
Skin Analytics wins because it leads on the dimensions carrying the greatest weight in this market: routine clinical use, autonomous regulatory authority, verified cancer outcomes, public contract value, and the ability to release scarce dermatologist capacity.
DermaSensor ranks second because FDA clearance gives it a powerful opening in the world’s largest healthcare market. Its rapid early growth, distinctive spectroscopy hardware, and $43 million funding base make it the company most capable of closing the gap. The next proof point is whether hundreds of physicians become large health-system deployments with high repeat usage.
SkinVision ranks third. Its direct consumer reach is unmatched, and its recent growth shows that people will repeatedly use smartphone skin checks. FDA clearance and verified links between app results, diagnoses, and healthcare savings could move SkinVision much closer to the top two.
AI Medical Technology is the most credible smaller challenger. Dermalyser has produced promising prospective results and reached European commercialization with limited funding. It now needs larger studies and visible customer adoption.
MetaOptima and SkinIO solve valuable monitoring problems, but their current evidence places them closer to clinical infrastructure than the front line of autonomous cancer assessment.
Skin Analytics could lose the lead if it fails to convert NHS success into international adoption or if NICE’s continuing evidence review exposes important limitations. DermaSensor could move into first place by scaling across U.S. health systems, improving referral precision, and resolving its open recall. SkinVision could reshape the category if FDA authorization turns millions of consumer checks into an insurer-funded clinical entry point.
| Rank | Startup | Why it ranks here |
|---|---|---|
| 1 | Skin Analytics | Strongest combination of autonomous regulation, routine clinical deployment, confirmed outcomes, public contracts, and pathway economics |
| 2 | DermaSensor | Clear U.S. leader with FDA clearance, rapid growth, distinctive hardware, and enough funding to expand aggressively |
| 3 | SkinVision | Unmatched consumer reach and software distribution, but weaker evidence of confirmed clinical and economic impact |
| 4 | AI Medical Technology | Strong early melanoma results and European clearance, with commercial scale still largely undisclosed |
| 5 | MetaOptima | Valuable imaging data and clinical workflow position, but limited proof of independent diagnostic leadership |
| 6 | SkinIO | Useful longitudinal monitoring product, with less funding, regulation, and clinical evidence than the leaders |
If you want more recent data on this point, please see our latest digital health market report.
OUR METHODOLOGY
This analysis compares startups operating across different parts of the AI skin cancer pathway, from consumer spot checks and clinical imaging to primary-care decision support and autonomous cancer triage. We did not rank them through one headline number because funding, users, scans, accuracy, and regulatory clearance measure very different things.
We broke the question into the dimensions that best reveal competitive progress: regulatory position, clinical evidence, real-world deployment, patient reach, commercial traction, growth, scalability, healthcare economics, defensibility, and capital efficiency.
For each dimension, we reviewed recent regulatory decisions, prospective studies, pathology-linked outcomes, patient and scan volumes, public procurement records, product launches, pricing, funding rounds, recalls, and disclosed adoption figures. We gave the greatest weight to first-hand records from regulators, public health authorities, procurement databases, peer-reviewed research, and the companies themselves.
We interpreted each figure according to what it actually proves. Consumer checks demonstrate distribution, confirmed cancers demonstrate clinical outcomes, public contracts demonstrate buyer commitment, and regulatory authorizations define what a product is legally allowed to do. These figures were not treated as interchangeable.
No single data point determined the final ranking. We identified the leader in each dimension, then looked for the company showing the strongest convergence across the areas carrying the most clinical and commercial weight.
Key sources include NICE guidance for DERM, NICE’s evidence standards, the Bradford procurement award, the FDA review of DermaSensor, the FDA recall record, DermaSensor’s operating and funding disclosure, SkinVision’s product data, the SkinVision–Mayo Clinic pivotal-trial announcement, the prospective Dermalyser study, and the prospective-study meta-analysis.
In our digital health market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- Which AI startup has the edge in medical imaging?
- Who is furthest ahead in early dementia detection?
